SAN FRANCISCO--(BUSINESS WIRE)--(NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging Awareness Day (NHAAD), observed annually to focus on the challenges facing the aging population with regards to HIV prevention, testing, care and treatment.
Let’s Kick ASS founder Tez Anderson, a long-term AIDS survivor, and Josh Robbins, an HIV positive patient advocate and GLAAD Award-nominated blogger for imstilljosh.com, are hosting a Facebook Live Conversation on Monday, September 18th at 12:00 p.m. PT to talk about important issues related to aging within the HIV+ / AIDS community.
This Facebook Live conversation is sponsored by Napo Pharmaceuticals, a wholly-owned subsidiary of Jaguar Health, Inc. You can watch live here: http://fb.com/imstilljosh.
During the live broadcast, Tez Anderson and Josh Robbins will discuss:
-
How long term survivors and newly diagnosed individuals can learn from
one another
- While Tez is a long-term survivor of HIV, Josh was more recently diagnosed (2012). Each brings to bear different perspectives about their journey living with HIV.
- This live discussion will honestly examine how the two sets of people living with HIV can offer wisdom and fresh perspectives to each other.
-
Some of the side effects of living with HIV
- The gastrointestinal (GI) tract - diarrhea, bloating and abdominal pain
- Skin - seborrheic dermatitis or skin rashes
- Mental health – depression, anxiety, mood changes
- Other – lipodystrophy, osteoporosis, osteopenia, diabetes, high blood pressure
Napo Pharmaceuticals recognizes the importance of HIV/AIDS and Aging Awareness Day, which it believes will increase significantly as the HIV+ population gets older. According to data from the U.S. Centers for Disease Control and Prevention, currently over 50% of people living with HIV are over age 50; by 2020 it will increase to 70 percent.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi® is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia™ is Jaguar’s non-prescription product for total gut health in equine athletes. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding possible follow-on indications for Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar-JAGX